Johnson & Johnson
J&J Gives Up On $230M Blood Pressure Drug After Disappointing Trial Results
Johnson & Johnson (J&J) is stepping back from its $230 million investment in a blood pressure treatment, aprocitentan, and returning ...
J&J cuts TB drug price by 55% after giving up patent rights
Just seven weeks after announcing its willingness to permit generic competition for the drug-resistant tuberculosis (TB) treatment Sirturo (bedaquiline) in ...
Bracing for Change: CMS Unveils Drug Price Negotiation Targets Amid Industry Backlash
The day that pharmaceutical manufacturers have been cautiously eyeing has finally dawned – Tuesday saw the grand revelation of the ...
Johnson & Johnson’s Strategic Move: Retains 9.5% Stake in Kenvue After Share-Exchange Offer
Following its share-exchange initiative aimed at reducing its stake in Kenvue, Johnson & Johnson has announced that it will maintain ...
Janssen’s Bispecific Antibody Tecvayli Receives European Commission Approval for Reduced Dosing Frequency
The Janssen Pharmaceutical Companies of Johnson & Johnson have proudly unveiled a significant advancement in cancer treatment. The European Commission ...
Carvykti CAR-T Therapy by J&J and Legend Biotech Persists Amid New Bispecific
Johnson & Johnson and Legend Biotech’s Carvykti maintains growth in the multiple myeloma market despite the emergence of a more ...
Pfizer’s Elrexfio Gets FDA Nod, Ignites Showdown with J&J in Multiple Myeloma Arena
Pfizer’s latest BCMA-targeted drug, Elrexfio (elranatamab), has gained FDA approval for treating multiple myeloma patients who have undergone at least ...
Johnson & Johnson Breaks Into Prostate Cancer Market with Akeega
After the FDA’s green light for AstraZeneca/Merck and Pfizer’s PARP inhibitors, Johnson & Johnson (J&J) has now secured its own ...
Supreme Court Halts Purdue Pharma’s Bankruptcy Deal That Shielded Sacklers From Opioid Lawsuits
The Supreme Court has put a halt to a massive bankruptcy settlement that would have shielded Purdue Pharma and the ...
Johnson & Johnson Takes Lead in Bispecific Antibody Approval for Multiple Myeloma, Leaving Pfizer in the Dust
The FDA has granted accelerated approval to talquetamab-tgvs, branded as Talvey, for treating relapsed or refractory multiple myeloma in adults ...
J&J Influencers Urge Parents to Check Kids’ Eyes
Johnson & Johnson (J&J) is launching a targeted marketing campaign for its recently FDA-approved overnight contact lenses, Acuvue Abiliti, to ...
After winning the J&J arbitration dispute, Alkermes, which is close to splitting its oncology business, saw a significant Q2 revenue increase
Alkermes is feeling confident about its prospects for the second half of 2023, after winning a big arbitration case against ...
Patients prefer ViiV’s injectable HIV medication, according to a Switch research
When ViiV Healthcare and Johnson & Johnson introduced their once-monthly injectable HIV treatment Cabenuva in 2021, they anticipated that patients ...
Johnson & Johnson intends to trade 80% of its Kenvue stock after the consumer split
Source – Johnson & Johnson With the completion of Johnson & Johnson’s consumer health spinoff, the company is now redirecting ...
Darzalex Continues Rising Trend – J&J Boosts Projected Yearly Revenues by $1 Billion
In 2017, Genmab CEO Jan van de Winkel envisioned that the multiple myeloma drug Darzalex, marketed by Johnson & Johnson, ...
J&J has been forced to compensate a mesothelioma sufferer $18.8 million in a talc dispute, but has vowed to appeal
During a period of nationwide freezing on Johnson & Johnson’s talc litigation, one case managed to proceed and resulted in ...
Positive Effects of Rybrevant Plus Chemotherapy in Early EGFR Exon 20 Insertion NSCLC
Source – Johnson & Johnson The combination of amivantamab-vmjw (Rybrevant) with the chemotherapy doublet carboplatin and pemetrexed has demonstrated a ...
Johnson & Johnson is the fourth pharmaceutical company to sue the IRA over its medicine price negotiations
Johnson & Johnson has joined the wave of litigation by becoming the fourth major pharmaceutical company to sue the US ...
J&J’s Rybrevant Wins in Rare Lung Cancer; Awaits Tagrisso Showdown
Source – Johnson & Johnson In 2021, Johnson & Johnson’s Rybrevant received accelerated approval from the FDA, becoming the first ...
Johnson & Johnson Files Lawsuit Against Four Doctors Over Alleged Biased Opinions in Talc Defense Cases
As Johnson & Johnson (J&J) seeks ways to address its talc-related legal challenges, the company has resorted to a new ...
Janssen rejoices at JNJ-2113A’s successful psoriasis study findings
Source – Johnson & Johnson On July 4, 2023, Janssen, a subsidiary of Johnson & Johnson announced positive initial results ...
Another Stelara patent settlement was reached by J&J, this time with Alvotech and Teva
Source – Johnson & Johnson By early 2025, a new settlement may allow for the entry of a second biosimilar ...
Johnson & Johnson (J&J) Moves Closer to FDA Approval for CAR-T Therapy
The company has filed for approval to use Carvykti earlier in the treatment pathway, including for patients experiencing their first ...
